Medpage Today on MSN

Checkpoint Blockade Finally Breaks Through in Ovarian Cancer

BERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall survival (OS) benefit in ovarian cancer, phase III study results showed.
The American Journal of Managed Care

Pembrolizumab Plus Chemo Boosts PFS, OS in Platinum-Resistant Recurrent Ovarian Cancer: Nicoletta Colombo, MD, PhD

KEYNOTE-B96 is the first trial to show overall survival (OS) improvement with an immune checkpoint inhibitor-based treatment ...